Form 8-K - Current report:
SEC Accession No. 0001104659-24-132132
Filing Date
2024-12-27
Accepted
2024-12-27 16:05:19
Documents
13
Period of Report
2024-12-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2431533d4_8k.htm   iXBRL 8-K 38876
  Complete submission text file 0001104659-24-132132.txt   214944

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rsls-20241219.xsd EX-101.SCH 3048
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rsls-20241219_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rsls-20241219_pre.xml EX-101.PRE 22381
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2431533d4_8k_htm.xml XML 3572
Mailing Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673
Business Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673 949-429-6680
ReShape Lifesciences Inc. (Filer) CIK: 0001427570 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37897 | Film No.: 241585763
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)